Revenues

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

REVENUES

Disaggregation of Revenues

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):



	Year Ended December 31, 2019								Year Ended December 31, 2018								Year Ended December 31, 2017⁽⁶⁾
	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
Atripla	$	501	$	60	$	39	$	600	$	967	$	131	$	108	$	1,206	$	1,288	$	335	$	183	$	1,806
Biktarvy	4,225		370		143		4,738		1,144		39		1		1,184		—		—		—		—
Complera/Eviplera	160		214		32		406		276		327		50		653		406		503		57		966
Descovy	1,078		255		167		1,500		1,217		308		56		1,581		958		226		34		1,218
Genvoya	2,984		664		283		3,931		3,631		794		199		4,624		3,033		534		107		3,674
Odefsey	1,180		438		37		1,655		1,242		335		21		1,598		964		132		10		1,106
Stribild	268		75		26		369		505		97		42		644		811		195		47		1,053
Truvada	2,640		101		72		2,813		2,605		260		132		2,997		2,266		644		224		3,134
Other HIV⁽¹⁾	30		5		12		47		40		7		14		61		43		6		9		58
Revenue share – Symtuza⁽²⁾	249		130		—		379		27		52		—		79		—		—		—		—
AmBisome	37		234		136		407		46		229		145		420		28		207		131		366
Ledipasvir/Sofosbuvir⁽³⁾	312		71		260		643		802		144		276		1,222		3,053		704		613		4,370
Letairis	618		—		—		618		943		—		—		943		887		—		—		887
Ranexa	216		—		—		216		758		—		—		758		717		—		—		717
Sofosbuvir/Velpatasvir⁽⁴⁾	971		553		441		1,965		934		654		378		1,966		2,404		869		237		3,510
Vemlidy	309		21		158		488		245		12		64		321		111		5		6		122
Viread	32		69		142		243		50		82		175		307		514		238		294		1,046
Vosevi	178		54		25		257		304		78		14		396		267		22		4		293
Yescarta	373		83		—		456		263		1		—		264		7		—		—		7
Zydelig	47		54		2		103		61		70		2		133		69		77		3		149
Other⁽⁵⁾	157		116		12		285		137		76		107		320		283		314		583		1,180
Total product sales	16,565		3,567		1,987		22,119		16,197		3,696		1,784		21,677		18,109		5,011		2,542		25,662
Royalty, contract and other revenues	80		244		6		330		72		310		68		450		85		300		60		445
Total revenues	$	16,645	$	3,811	$	1,993	$	22,449	$	16,269	$	4,006	$	1,852	$	22,127	$	18,194	$	5,311	$	2,602	$	26,107



_________________________________________
(1)	Includes Emtriva and Tybost.
(2)	Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC (Janssen).
(3)	Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.
(4)	Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
(5)	Includes Cayston, Hepsera and Sovaldi.
(6)	The information for the year ended December 31, 2017 has not been adjusted in accordance with our modified retrospective adoption of Topic 606 and continues to be reported in accordance with our historical accounting under Topic 605.

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $741 million and $541 million for the years ended December 31, 2019 and 2018, respectively. Changes in estimates for variable consideration related to sales made in prior years resulted in a $257 million increase and a $56 million decrease in revenues for the years ended December 31, 2019 and 2018, respectively.

Contract Balances

Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $144 million and $125 million as of December 31, 2019 and 2018, respectively. Contract liabilities were not material as of December 31, 2019 and 2018.